NCT05905731进行中（未招募）1 期
Study Evaluating the Safety and Efficacy of Autologous T-cells Transfected With mRNA Encoding Hepatitis-B Virus (HBV)-Antigen-specific T Cell Receptor (TCR) in Combination With Nucleos(t)Ide Analogue (NUC) for Chronic Hepatitis B
Beijing 302 Hospital2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2023年6月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- Safety evaluation of HBV-TCR T cell treatment
研究概览
简要总结
This is a single center, single arm, open label study to assess the safety, tolerability and effectiveness of the autologous HBV specific T cell receptor (HBV-TCR) redirected T cells in patients with chronic hepatitis B with ongoing with nucleos(t)ide analogue (NUC) treatment. This study will be conducted sequentially starting with Stage-1, followed by Stage-2.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •HBsAg Positive, HBeAg Negative, Anti-HBe Positive (with HBeAg seroconversion).
- •On first-line treatment with oral nucleoside analogs antiviral drug therapy for more than a year.
- •Adequate organ function
- •Willing to stop and/or not to be on other immunomodulators during the study period, and to inform in time when other treatments such as glucocorticoids are needed
- •Liver biopsy, Fibroscan® or equivalent test obtained within the past 6 months demonstrating liver disease consistent with chronic HBV infection without evidence of bridging fibrosis or cirrhosis (≥ Metavir 3, recommended cut-off for Fibroscan 9.0kPa)
- •Females of childbearing potential must have a negative pregnancy test at Screening (within 3 days prior to first dose) and be willing to have additional pregnancy tests during the study. Females considered not of childbearing potential include those who have been in menopause at least 2 years, or had tubal ligation at least 1 year prior to Screening, or who have had total hysterectomy. Willing and able to comply with all study procedures.
- •Willing and able to provide written, signed informed consent after the nature of the study has been explained, and prior to any research-related procedures.
排除标准
- •History of Acute infection, gastrointestinal bleeding, etc. occurring within 28 days prior to study enrollment.
- •Advanced liver cirrhosis, Child-Pugh score ≥ 7 or clinical symptoms of liver function decompensation such as ascites and varicose veins
- •Positive test for other viral infections, anti-HAV IgM, anti HCV, anti-HDV, anti -HEV and anti-HIV Any item is positive; liver disease caused by other reasons (such as autoimmune liver disease, alcoholic liver disease, non-alcoholic liver disease, drug-induced liver disease and other liver diseases of unknown cause, etc.).
- •History of or suspicion of hepatocellular carcinoma or alpha fetoprotein (AFP) > 20 ng/mL at Screening. If AFP > 20 ng/mL, hepatic imaging must exclude hepatocellular carcinoma.
- •History of having received (in the last 6 months) or currently receiving any other cell therapies
- •History of organ transplantation
- •History of severe allergic reaction (hives or anaphylaxis) to blood products
- •History of any Grade 4 immune-related AE from prior immunotherapy. Any immune-related AE that led to permanent discontinuation that occurred less than 6 months prior to leukapheresis or whole blood collection for production
- •Use of any investigational product (IP) within 28 days of study treatment administration.
- •Lack of peripheral venous or central venous access or any condition that would interfere with drug administration or collection of study samples
结局指标
主要结局
Safety evaluation of HBV-TCR T cell treatment
时间窗: Start of Treatment until 28 days post last dose
Incidence of adverse events/serious adverse events
次要结局
- To evaluate the capability of HBV-TCR T cell treatment to lower the levels of serum HBsAg(Start of treatment until 12 months post treatment follow-up)
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
早期 1 期
A Study on the Treatment of Parkinson's Disease With Autologous Neural Stem CellsParkinson DiseaseNCT03815071Allife Medical Science and Technology Co., Ltd.10
Unknown
早期 1 期
A Study of Autologous Induced Islet Body With Type 1 DiabetesType 1 DiabetesNCT03728296Allife Medical Science and Technology Co., Ltd.20
Unknown
1 期
IIT Study of M1-c6v1 Combined With SHR-1210 and Apatinib in Patients With HCCAdvanced/Metastatic Hepatocellular CarcinomaNCT04665362Liang Peng10
进行中（未招募）
1 期
Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPCMetastatic Castration-resistant Prostate CancerCastration-resistant Prostate CancerNCT06228404Shanghai Changzheng Hospital18
招募中
1 期
Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple MyelomaMultiple MyelomaNCT05549973Institute of Hematology & Blood Diseases Hospital, China32